SAN DIEGO, Nov. 21, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in fireside chats and 1x1 investor meetings at the 34th Annual Piper Sandler Healthcare Conference and the JMP Securities Hematology and Oncology Summit taking place on November 29 – December 1, 2022, and December 6 – 7, 2022, respectively.
Details of the fireside chats can be found below.
34th Annual Piper Sandler Healthcare Conference
Date: | Tuesday, November 29, 2022 |
Time: | 1:30 – 1:55 PM ET |
Conference Location: | New York, NY |
Webcast Link: |
The JMP Securities Hematology and Oncology Summit
Date: | Wednesday, December 7, 2022 |
Time: | 3:00 – 3:15 PM ET |
Conference Location: | Virtual |
Webcast Link: |
Replays of the fireside chats will be available by visiting the "Events" section of the Cardiff Oncology website and will be archived for 90 days.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor we are evaluating in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as KRAS/NRAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC). These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$4.07 |
Daily Change: | 0.08 2.01 |
Daily Volume: | 482,590 |
Market Cap: | US$181.850M |
February 29, 2024 February 29, 2024 February 29, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB